Prevalence and Mechanisms of Low Level Quinolone Resistance among Non-Typhoidal Salmonella Isolates from Human and poultry/Livestock in Korea: Usefulness of Nalidixic Acid Resistance Test
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Non-typhoidal Salmonella (NTS) are important commensal microorganisms. We intended to investigate the prevalence and mechanisms of nalidixic acid resistance among NTS isolated from human and poultry/livestock. Methods: A total of 151 Salmonella isolates (36 human and 115 livestock isolates,respectively) was tested for the Minimum inhibitory concentrations (MICs) of nalidixic acid, together with serotyping. As for the nalidixic acid resistant isolates,further studies were taken: MICs of ciprofloxacin, mutation analysis of gyrA and parC genes, and organic solvent tolerance test. Results: Eighty-four isolates of 151 human and livestock isolates were resistant to nalidixic acid. The prevalence of nalidixic acid resistance and was 13.9% (5of 36 isolates) in human isolates and 68.7% (79 of 151 isolates), in the livestock isolates respectively. Among 84 nalidixic acid-resistant isolates, the The prevalence of ciprofloxacin resistance in livestock isolates was 24.1% (1 resistant and 18intermediate of 79 strains), but no ciprofloxacin resistance was found in 5 human isolates. Among 65 nalidixic acid resistant, ciprofloxacin-susceptible isolates, 3(60%, of 5 human isolates) and 60 (100%, all livestock isolates) showed low level fluoroquinolone resistance (ciprofloxacin MIC, 0.125-1.0 μg/μL). Six types of point mutations were found in the analysis of DNA sequencing of the gyrA gene in the 84isolates; 75 isolates showed point mutations on amino acid Ser 83 and/or Asp 87. On the other hand, no point mutation was found from the parC genes. Forty-seven nalidixic acid resistant isolates showed tolerance to organic solvents. Conclusions: Nalidixic acid resistance was a good marker of low level fluoroquinolone resistance. As for the severe NTS infection, MIC test for nalidixic acid would be required.
Abstract
Background: Non-typhoidal Salmonella (NTS) are important commensal microorganisms. We intended to investigate the prevalence and mechanisms of nalidixic acid resistance among NTS isolated from human and poultry/livestock. Methods: A total of 151 Salmonella isolates (36 human and 115 livestock isolates,respectively) was tested for the Minimum inhibitory concentrations (MICs) of nalidixic acid, together with serotyping. As for the nalidixic acid resistant isolates,further studies were taken: MICs of ciprofloxacin, mutation analysis of gyrA and parC genes, and organic solvent tolerance test. Results: Eighty-four isolates of 151 human and livestock isolates were resistant to nalidixic acid. The prevalence of nalidixic acid resistance and was 13.9% (5of 36 isolates) in human isolates and 68.7% (79 of 151 isolates), in the livestock isolates respectively. Among 84 nalidixic acid-resistant isolates, the The prevalence of ciprofloxacin resistance in livestock isolates was 24.1% (1 resistant and 18intermediate of 79 strains), but no ciprofloxacin resistance was found in 5 human isolates. Among 65 nalidixic acid resistant, ciprofloxacin-susceptible isolates, 3(60%, of 5 human isolates) and 60 (100%, all livestock isolates) showed low level fluoroquinolone resistance (ciprofloxacin MIC, 0.125-1.0 μg/μL). Six types of point mutations were found in the analysis of DNA sequencing of the gyrA gene in the 84isolates; 75 isolates showed point mutations on amino acid Ser 83 and/or Asp 87. On the other hand, no point mutation was found from the parC genes. Forty-seven nalidixic acid resistant isolates showed tolerance to organic solvents. Conclusions: Nalidixic acid resistance was a good marker of low level fluoroquinolone resistance. As for the severe NTS infection, MIC test for nalidixic acid would be required.
참고문헌 (35)
- San Martin B, "Isolation and molecular characterization of quinolone resistant Salmonella spp . from poultry farms", Vet Microbiol, 110, pp.239~244 (2005)
- Marimon JM, "Increasing prevalence of quinolone resistance in human nontyphoid Salmonella enterica isolates obtained in Spain from 1981 to 2003", Antimicrob Agents Chemother, 48, pp.3789~3793 (2004)
- Hakanen A, "Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test", J Clin Microbiol, 37, pp.3572~3577 (1999)
- Breuil J, "Antibiotic resistance in salmonellae isolated from humans and animals in France: comparative data from 1994 and 1997", J Antimicrob Chemother, 46, pp.965~971 (2000)
- Hakanen A, "Increasing fluoroquinolone resistance in Salmonella serotypes in Finland during 1995-1997", J Antimicrob Chemother, 43, pp.145~148 (1999)
- Herikstad H, "Emerging quinolone-resistant Salmonella in the United States", Emerg Infect Dis, 3, pp.371~372 (1997)
- Mølbak K, "Increasing quinolone resistance in Salmonella enterica serotype Enteritidis", Emerg Infect Dis, 8, pp.514~515 (2002)
- Prats G, "Antibiotic resistance trends in enteropathogenic bacteria isolated in 1985-1987 and 1995-1998 in Barcelona", Antimicrob Agents Chemother, 44, pp.1140~1145 (2000)
- Seral C, "Quinolone resistance in Salmonella enterica", Rev Esp Quimioter, 11, pp.43~46 (1998)
- Threlfall EJ, "Resistance to ciprofloxacin in non-typhoidal salmonellas from humans in England and Walesthe current situation", Clin Microbiol Infect, 5, pp.130~134 (1999)
- Walker RA, "Use of a Light Cycler gyrA mutation assay for rapid identification of mutations conferring decreased susceptibility to ciprofloxacin in multiresistant Salmonella enterica serotype Typhimurium DT104 isolates", J Clin Microbiol, 39, pp.1443~1448 (2001)
- Hirose K, "DNA sequence analysis of DNA gyrase and DNA topoisomerase IV quinolone resistance-determining regions of Salmonella enterica serovar Typhi and serovar Paratyphi A", Antimicrob Agents Chemother, 46, pp.3249~3252 (2002)
- Liebana E, "Comparison of gyrA mutations, cyclohexane resistance, and the presence of class I integrons in Salmonella enterica from farm animals in England and Wales", J Clin Microbiol, 40, pp.1481~1486 (2002)
- Reche MP, "gyrA Mutations associated with nalidixic acid-resistant salmonellae from wild birds", Antimicrob Agents Chemother, 46, pp.3108~3109 (2002)
- Clinical and Laboratory Standards Institute, "Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 7th ed. Document M7-A7, Wayne, PA, 2006", ~ (2006)
- Popoff MY, "Supplement 1997 (no. 41) to the Kauffmann-White scheme", Res Microbiol, 149, pp.601~604 (1998)
- Asako H, "Organic solvent tolerance and antibiotic resistance increased by overexpression of marA in Escherichia coli", Appl Environ Microbiol, 63, pp.1428~1433 (1997)
- Oethinger M, "Association of organic solvent tolerance and fluoroquinolone resistance in clinical isolates of Escherichia coli", J Antimicrob Chemother, 41, pp.111~114 (1998)
- Threlfall EJ, "Antimicrobial drug resistance in Salmonella : problems and perspectives in food- and water-borne infections", FEMS Microbiol Rev, 26, pp.141~148 (2002)
- Hakanen AJ, "Reduction in fluoroquinolone susceptibility among non-typhoidal strains of Salmonella enterica isolated from Finnish patients", J Antimicrob Chemother, 57, pp.569~572 (2006)
- Murray A, "Ciprofloxacin resistance in non-typhoidal Salmonella serotypes in Scotland, 1993-2003", J Antimicrob Chemother, 56, pp.110~114 (2005)
- Chang CM, "Cefotaxime-ciprofloxacin combination therapy for nontyphoid Salmonella bacteremia and paravertebral abscess after failure of monotherapy", Pharmacotherapy, 26, pp.1671~1674 (2006)
- Heisig P, "High-level fluoroquinolone resistance in a Salmonella Typhimurium isolate due to alterations in both gyrA and gyrB genes", J Antimicrob Chemother, 32, pp.367~377 (1993)
- Bauernfeind A, "A new plasmidic cefotaximase from patients infected with Salmonella Typhimurium", Infection, 20, pp.158~163 (1992)
- Digranes A, "Antibiotic susceptibility of blood culture isolates of Enterobacteriaceae from six Norwegian hospitals 1991-1992", APMIS, 105, pp.854~860 (1997)
- Chung TH, "Study on the Genus Salmonella cultures isolated in Korea 1982", J Korean Soc Microbiol, 18, pp.31~38 (1983)
- Stevenson JE, "Increase in nalidixic acid resistance among non-Typhi Salmonella enterica isolates in the United States from 1996 to 2003", Antimicrob Agents Chemother, 51, pp.195~197 (2007)
- Choi SH, "Increasing incidence of quinolone resistance in human nontyphoid Salmonella enterica isolates in Korea and mechanisms involved in quinolone resistance", J Antimicrob Chemother, 56, pp.1111~1114 (2005)
- Hee Jin Cheong, "Characteristics of Non-typhoidal Salmonella Isolates from Human andBroiler-chickens in Southwestern Seoul, Korea", Journal of Korean Medical Science, 22(5), pp.773~778 (2007), 대한의학회
- Helms M, "Excess mortality associated with antimicrobial drug-resistant Salmonella Typhimurium", Emerg Infect Dis, 8, pp.490~495 (2002)
- Asna SMZ, "Nalidixic acid-resistant Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin caused treatment failure: a report from Bangladesh", Jpn J Infect Dis, 56, pp.32~33 (2003)
- Aarestrup FM, "Is it time to change fluoroquinolone breakpoints for Salmonella spp.?", Antimicrob Agents Chemother, 47, pp.827~829 (2003)
- Parry CM, "Antimicrobial drug resistance in Salmonella enterica", Curr Opin Infect Dis, 16, pp.467~472 (2003)
- Eaves DJ, "Prevalence of mutations within the quinolone resistance-determining region of gyrA, gyrB, parC, and parE and association with antibiotic resistance in quinolone-resistant Salmonella enterica", Antimicrob Agents Chemother, 48, pp.4012~4015 (2004)
- Mølbak K, "An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype Typhimurium DT104", N Engl J Med, 341, pp.1420~1425 (1999)